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Allopurinol is a scavenger of the highly reactive hydroxyl radical {kp approx. IO9 M-‘*s-I). One product 
of attack of hydroxyl radical upon allopurinol is oxypurinol, which is a major metabolite of allopurinol. 
Oxypurinol is a better hydroxyl radical scavenger than is allopurinol (k2 approx. 4 x lo9 M-‘*s-l) and 
it also reacts with the myeloperoxidase-derived oxi ant hypochlorous acid. Hence the protective actions 
of allopurinol against reperfusion damage after hypoxia need not be entirely due to xanthine oxidase inhibi- 
tion. 
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1, INTRODUCTION 
Oxygen radicals play some part in mediating 
reperfusion damage after ischaemia in animal 
tissues [l] and the enzyme superoxide dismutase 
(SOD) has significant protective effects in in- 
testinal, renal, cardiac and skin-flap animal model 
systems [2,3]. Superoxide dismutase is a specific 
scavenger of superoxide radical, 02. Superoxide 
may have some direct cytotoxic effect [4], but it 
also accelerates the formation of hydroxyl radical 
from hydrogen peroxide in the presence of suitable 
transition metal catalysts [5,6]. Hydroxyl radical is 
much more reactive than 02; it can attack almost 
all cell constituents and it initiates the process of 
lipid peroxidation [6]. Indeed, scavengers of 
hydroxyl radical (e.g. mannitol, dimethyl sulphox- 
ide) and inhibitors of lipid peroxidation (e.g. cy- 
tocopherol) often show partial protective effects 
against reperfusion injury in animal model or 
isolated organ systems (e.g. [7-111). 
An important source of 02 in ischaemic/reper- 
fusion injury in intestine is probably the enzyme 
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xanthine oxidase, produced from xanthine 
dehydrogen~e during the ischaemic phase [2]. 
Xanthine oxidase has been detected in rat [ 101 and 
dog [I I] heart, but its activity in human heart is 
unclear [ 121. It is possible that 0; radicals 
generated by activated phagocytes invading a 
reperfused myocardial infarct are also important 
in vivo [13,14]. 
Often (e.g. [3,11,15,16]) the only evidence 
presented for the importance of xanthine oxidase 
as a radical generator in ischaemic/reperfused 
tissue is the partial protection observed with 
allopurinol, an inhibitor of xanthine oxidase 
[ 17,181. Allopurinol is usually given to animals in 
large intravenous bolus dose (e.g. 30-50 mglkg) 
on occlusion of the blood supply, and often addi- 
tionally the animals are pre-treated with it. For ex- 
ample, 50 mg (0.37 mmol) per kg intravenous 
allopurinol decreased reperfusion damage in cat 
intestine to about the same extent as 20 mg 
(0.26 mmol) per kg intravenous dimethyl sulphox- 
ide, used as a scavenger of hydroxyl radicals [19]. 
Allopurinol has also been included in the reperfu- 
sion media of isolated organs at millimolar concen- 
trations [ 161. 
Allopurinol has a structure related to purines, 
and it is well known that aromatic compounds are 
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powerful hydroxyl radical scavengers [20]. Indeed, 
serum uric acid has been proposed to be an impor- 
tant antioxidant in humans [21]. This led us to ex- 
amine the radical-scavenging activity of allopu- 
rinol . 
When animals are pre-treated with allopurinol, 
they will form oxypurinol(4,6-dihydroxypyrazolo- 
[3,4_d]pyrimidine), which is a major metabolite of 
allopurinol [18,23]. It was thus of interest to com- 
pare the radical-scavenging activity of allopurinol 
with that of oxypurinol. 
2. MATERIALS AND METHODS 
2.1. Reagents 
Deoxyribose, FeC13, allopurinol and oxypurinol 
were from Sigma. Phenol, catechol, resorcinol and 
hydroquinone were from Aldrich. HPLC solvents 
and all other reagents were of the highest quality 
available from BDH Chemicals. 
2.2. Assay of hydroxyl radical production 
Aromatic hydroxylation with phenol as 
substrate was carried out as in [25]. The deox- 
yribose assay [24] was carried out by incubating, in 
a final volume of 1 .O ml, the following reagents at 
the final concentrations stated: deoxyribose 
(variable), KHzPOd-KOH buffer, pH 7.4 
(20 mM), FeC13 (100 PM), EDTA (104 PM), Hz02 
(1 mM), ascorbate (100 PM). After incubation 
with gentle shaking at 37’C for 1 h, colour was 
developed as in [24]. Preliminary HPLC experi- 
ments (for details of methodology see [32]) showed 
that exposure of allopurinol and oxypurinol to 
strongly alkaline solutions could cause their 
degradation, so solutions were made up at pH < 
10 and their exact concentrations determined using 
a molar absorption coefficient of 7400 M-l. cm-’ 
for allopurinol (253 nm) and 9200 M-r *cm-’ 
(242 nm at pH 10.5) for oxypurinol [26]. 
3. RESULTS 
3.1. Deoxyribose assay 
Deoxyribose is attacked by hydroxyl radicals 
(‘OH) to form a product that reacts, on heating 
with thiobarbituric acid (TBA), to form a pink 
chromogen (A,,, 532 nm) [24]. Hydroxyl radicals 
were generated by a mixture of Fe3+, ascorbic acid 
and Hz02 in the presence of a slight excess of 
24 
EDTA over the iron salt [27], according to the 
reactions [24,28,29], 
Fe3+-EDTA + ascorbate ---+ Fe2+-EDTA + 
oxidised ascorbate (1) 
Fe2+-EDTA + Hz02 - Fe 3+-EDTA + ‘OH + 
OH- (2) 
‘OH + deoxyribose -+ 
heat with 
product p 
TBA 
chromogen (3) 
Any ‘OH radicals that escape scavenging by the 
EDTA, which is present in slight excess over iron 
ions, will be equally accessible to deoxyribose and 
Table 1 
Inhibition of deoxyribose degradation by allopurinol, 
oxypurinol, dimethyl sulphoxide and mannitol 
Scavenger added Con- % inhibition of deoxy- 
cen- ribose degradation 
tra- 
tion 
(mM) 0.33FmM 
At 
2.68 mM 
deoxyribose deoxyribose 
None - 0 0 
Allopurinol 0.5 57 17 
1.0 62 22 
1.5 73 32 
Dimethyl sulphoxide 0.5 86 71 
1.0 93 78 
1.5 94 80 
Mannitol 0.5 46 7 
1.0 58 18 
1.5 66 26 
Oxypurinol 0.5 70 25 
1.0 76 55 
1.5 83 67 
A typical experiment is shown. The extents of 
deoxyribose degradation corresponding to 0% inhibition 
(no scavenger added) were, as As32 values, 0.887 
(0.336 mM deoxyribose) and 2.209 (2.68 mM 
deoxyribose). All concentrations stated were final 
concentrations in reaction mixtures. In a series of 
experiments, the inhibition by allopurinol was generally 
similar to that produced by mannitol but the inhibition 
by oxypurinol was greater 
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to any other added molecule that reacts with ‘OH 
[28]. Table 1 shows that mannitol and dimethyl 
sulphoxide, two established scavengers of ‘OH, in- 
hibited deoxyribose degradation, presumably by 
competing with it for the ‘OH generated in the 
reaction mixture. Indeed, raising the deoxyribose 
concentration lessened the inhibition by fixed con- 
centrations of mannitol or dimethyl sulphoxide, as 
expected (table 1). Both allopurinol and ox- 
ypurinol also inhibited the deoxyribose degrada- 
tion (table 1). In a range of experiments, the 
inhibitory effect of allopurinol was comparable to 
that of mannitol, but that of oxypurinol was 
greater. Neither compound was as inhibitory as 
dimethyl sulphoxide. 
Fig.1 shows that the inhibition by allopurinol 
and oxypurinol followed simple competition 
kinetics. From the slopes of the lines approximate 
second-order rate constants for the reactions be- 
tween these substances and ‘OH were obtained. 
Values for allopurinol, in a series of six ex- 
periments, ranged from 0.84 x lo9 to 2.86 x 109, 
mean value 1.81 x lo9 M-‘-s-‘. Values for ox- 
14iB J 
Fig.1. Inhibition of deoxyribose degradation by 
allopurinol and oxypurinol. A typical experiment is 
shown. Both deoxyribose and scavenger concentrations 
were varied and the extent of deoxyribose degradation 
determined as &2. Plots of l/AS32 versus [allopurinol] 
or [oxypurinol] are linear, confirming a competition 
between these molecules and deoxyribose for ‘OH. The 
rate constants were calculated as k = slope.knn[DR]A’ 
where the rate constant for reaction of deoxyribose with 
‘OH (knn) is taken as 1.9 x lo9 M-’ as-’ (0) 0.336 mM 
deoxyribose, variable allopurinol (A) or oxypurinol (B) 
concentrations, (m) 2 mM deoxyribose, variable 
oxypurinol (B) or allopurinol (A) concentrations. 
WL 0 
MINUTES 
Fig.2. Formation of oxypurinol during attack of 
hydroxyl radical upon allopurinol. HPLC was carried 
out on a pre-packed 4.6 mm x 25 cm Anachem S5 
ODS-2 column with an Anachem S5 ODS-2 guard 
column. The mobile phase was 54.5% (v/v) 30 mM 
sodium titrate/27.7 mM sodium acetate buffer, pH 
4.75, and 45.5% methanol at a flow rate of 1.10 ml/min 
continuously sparged with helium. Detection of 
hydroquinone (HQ), catechol (CTC) and oxypurinol 
(OP) by HPLC was by electrochemical detection at 
0.78 V. Typical retention times for hydroquinone, 
oxypurinol, catechol and phenol using the above eluent 
were 5.42, 5.40, 7.36 and 10.34 min respectively. 
Oxypurinol was a minor product of the reaction of 
allopurinol with ‘OH, e.g. only 4.5 pM oxypurinol was 
produced in reaction mixtures containing 2 mM 
allopurinol and 1 mM phenol. na, nanoamps; ASC, 
ascorbic acid. 
25 
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Table 2 
Inhibition of phenol hydroxylation by allopurinol, oxypurinol and mannitol 
Scavenger added Concen- Amount of hydroxylated product % 
tration inhibition 
(mM) Catechol Hydroquinone Total 
None 41.6 28.8 70.4 0 
Mannitol 1 31.4 23.2 54.6 22 
2 23.7 18.7 42.4 40 
Ailopurinol 1 29.7 21.7 51.4 27 
2 25.2 17.3 42.5 40 
Oxypurinol 1 22.4 16.8 39.2 44 
2 13.4 10.2 23.6 66 
Reaction mixtures contained, in a final volume of 1 .O ml, the following reagents added 
in the order stated to give the final concentrations in brackets; KHzPO&OH buffer, 
pH 7.4 (20 mM); EDTA (1OOpM); phenol (1 mM); allopurinol, oxypurinol or 
mannitol (see below); Hz02 (100 pM); FeCL (100 PM); ascorbate made up 
immediately before use in deaerated water (100~M). Reaction mixtures were 
incubated at 37’C for 30 min and a 20~1 sample injected into the HPLC system 
[20,251. Results are means of duplicates that differed by 12% or less. Vo inhibitions 
are calculated using the figure for total hydroxylat~ product formed 
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ypurinol, in four separate experiments, ranged 
from 3.05 x lo9 to 7.14 x 109, mean value 4.27 x 
IO9 M-“+s-‘. Similar competition plots for man- 
nitoi (not shown) gave values in the range 1 x 
109-2 x lo9 M-’ - S-I and for dimethyl suiphoxide 
values in the range 7 x 109-1 x 10” M-‘*s-l. 
These values compare well with published rate con- 
stants, determined by pulse radiolysis, for man- 
nitol (109-1.8 x IO9 [30]) and dimethyl sulphoxide 
(7 x lo9 [31]). 
3.2. Aromatic hydroxylation assay 
In order to confirm the scavenging ability of 
allopurinol and oxypurinol, a completely different 
detector molecule for ‘OH was used. Phenol is at- 
tacked by ‘OH to give a mixture of catechol and 
hydroquinone, which can easily be separated by 
HPLC (251. Table 2 shows a typical experiment. It 
may be seen that mannitol inhibits phenol hydrox- 
ylation, presumably by competing for the available 
‘OH radicals [ZS]. The inhibition by allopurinol 
was comparable to that produced by mannitol, but 
the inhibition by oxypurinol was greater. 
Fig.2 shows that HPLC analysis of a reaction 
mixture containing allopurinol and an ‘OH- 
generating system (legend to table 2) gave a peak 
running at the retention time for oxypurino!, Fig.3 
26 
confirms the identity of this peak as oxypurinol by 
comparing its electrochemical behaviour with that 
of an authentic sample of oxypurinoi. Hence at- 
tack of *OH radical upon ~lopurinol produces, 
among other products, oxypurinol. 
Fig.3. Electrochemical evidence for the identity of the 
putative oxypurinol peak formed on exposing 
allopurinol to a system generating hydroxyl radicals. 
The oxidation potential of the eIe~tro~hemica1 detector 
was varied and the height of the putative oxypurinol 
peak (fig.2) was measured. The relative peak height is 
plotted as a function of oxidation potential (0). A 
similar experiment was conducted with authentic 
oxypurinol (A). It may be seen that the two curves match 
closely. 
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4, DISCUSSION 
Allopurinol is a powerful scavenger of ‘OH 
radicals, with an effectiveness comparable to that 
of mannitol in both deoxyribose and aromatic 
hydroxylation assays, suggesting that its second- 
order rate constant for reaction with *OH is about 
IO9 M-r -sml. Considering the large amounts of 
allopurinol that have been used with isolated 
organs and animal model systems of 
ischaemia/reperfusion damage (see section l), 
together with the protective effects of ‘OH 
scavengers (such as mannitol and dimethyl 
sulphoxide) frequently reported in such systems, it 
may be seen that protection by allopurinol cannot 
be taken as evidence that xanthine oxidase is im- 
portant in mediating the reperfusion damage. It 
follows that an inhibitory effect of allopurinol can- 
not be used as the sole evidence that xanthine ox- 
idase is present in a system. Oxypurinoi, a major 
metabolite of allopurinol, is an even better ‘OH 
radical scavenger than is allopurinol, which further 
complicates in vivo studies in which animals are 
pre-treated with allopurinol. Although in the feline 
intestine [2,221 and dog heart [ 1 l] model systems, 
other evidence supports a role for xanthine ox- 
idase, this need not necessarily be true for other 
systems. It must also be noted that oxypurinol is a 
scavenger of the myeioperoxidase-derived oxidant 
h~~hlorous acid [32f, which may cause some 
tissue damage during reperfusion in vivo [33]. 
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